ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Evaluation of 1H-pyrazol-1-yl benzenesulfonamide derivatives in alleviating inflammatory bowel disease via PI3K/Akt/mTOR signaling pathway in zebrafish models.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of inflammatory bowel disease (IBD) is increasing in developed nations, leading to a significant increase in healthcare expenses. It is characterized by chronic intestinal inflammation driven by excessive oxidative stress and dysregulated immune responses, leading to epithelial injury and impaired mucosal healing. Existing treatments have adverse effects, patient noncompliance issues, and high costs, emphasizing the need for new treatments. Pyrazole derivatives are promising antioxidant and anti-inflammatory bioactive compounds. This study uses zebrafish to test 1H-pyrazol-1-yl benzenesulfonamide derivatives for IBD treatment. Through network pharmacology and molecular docking, various 1H-pyrazol-1-yl benzenesulfonamide derivatives were screened, and T8 (4-(5-(4-chlorophenyl)-3-(2-(4-phenoxybenzylidene)hydrazine-1-carbonyl)-1H-pyrazol-1-yl)benzenesulfonamide) was chosen for in vitro and in vivo evaluation. T8 at 200 μM exhibited dose-dependent antioxidant (> 80%) and anti-inflammatory (> 85%) activities in vitro. In the zebrafish intestine, administering T8 at 150 μM led to a reduction in reactive oxygen species (ROS) (2.97-fold), lipid peroxidation, cellular apoptosis (2.30-fold), and macrophage accumulation. It restored superoxide dismutase (SOD) (19.49 U/mg) and catalase (CAT) (0.54 U/mg) levels while reducing malondialdehyde (MDA) (0.44 μmol), lactate dehydrogenase (LDH) (0.23 U/mg), and nitric oxide (NO) (3.61 μmol) levels. The expression levels of proinflammatory cytokines in zebrafish intestines were significantly reduced due to T8 suppressing the PI3K/Akt/mTOR signaling pathway. The gut histoarchitecture was restored after T8 treatment, as shown by histological analysis. By modulating the PI3K/Akt/mTOR signaling pathway, T8 reduced inflammation and oxidative stress in zebrafish, reducing IBD symptoms.
Indexed as
Identifiers
41288677What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.